JBCHEPHARM - Investment Analysis

Last Updated Time : 02 Aug 25, 12:58 am

📊 Investment Analysis: JB Chemicals & Pharmaceuticals Ltd. (JBCHEPHARM)

Investment Rating: 4.3

💊 Fundamental Snapshot

ROE: 20.1% & ROCE: 25.8% — very healthy returns, especially for a pharma mid-cap; strong indicators of efficiency.

EPS: ₹42.4 vs. P/E: 44.1 — slightly expensive relative to sector average (PE: 34.0), but premium seems justified due to margin consistency.

PEG Ratio: 2.06 — valuation slightly ahead of earnings growth; not alarming, but future upside may be tempered.

Debt-to-Equity: 0.01 — ultra-low leverage; excellent capital structure.

Dividend Yield: 0.86% — modest, not a strong income play but supports stable cash flow management.

📌 Good margin structure, low debt, solid returns — checks several boxes for quality long-term hold.

📉 Technical View

RSI: 71.8 — overbought zone; suggests caution for fresh entry.

MACD: +12.9 — bullish crossover; short-term momentum intact.

DMA Comparison: Price well above 50 & 200 DMA — trend is strong, but entry at current levels risky without pullback.

Volume Surge (2x avg) — suggests institutional activity or breakout; be alert for profit booking.

🎯 Ideal Entry Price Zone: ₹1,640 – ₹1,710 Look for retracement near 50 DMA (~₹1,679) and historical support zones to enter with better margin of safety.

🧭 Holding / Exit Strategy

✅ Hold Strategy

Recommended Holding Period: 2–4 years

Continue holding if

ROE sustains >18% and ROCE stays >22%

EPS trends >₹50+ within 6 quarters

PAT crosses ₹160 Cr+ consistently with margin expansion

PEG Ratio trends below 1.8, indicating price aligns better with growth

🚪 Exit Plan

Partial Exit: ₹2,000–₹2,030 — ideal zone to book profits if fundamentals aren’t catching up

Full Exit If

Price dips below ₹1,600 with volume spike and bearish crossover

EPS stagnates under ₹43 for 3+ quarters

Institutional holding trends continue declining

RSI remains >70 with flattening MACD and weak profit growth

JB Chemicals shows signs of a well-run pharma business with consistent profitability and low debt—but premium pricing warrants tactical patience. If you want to compare with peers like Glenmark or Ipca for diversification across formulations, I can map that out next 🔬📈

Edit in a page